Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$1.13 -1.8%	$1.29	$0.85 ▼ $4.40	$37M	0.25	31,698 shs	28,281 shs
KYTX Kyverna Therapeutics	$3.07 +5.5%	$2.45	$1.78 ▼ $11.40	$125.77M	2.52	380,145 shs	413,320 shs
NMRA Neumora Therapeutics	$0.79 +0.7%	$0.75	$0.61 ▼ $17.19	$126.16M	2.73	1.54 million shs	874,997 shs
RAPT Rapt Therapeutics	$7.43 +0.1%	$7.46	$5.67 ▼ $30.60	$122.70M	-0.11	161,581 shs	152,905 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	-1.78%	-11.51%	-24.84%	-59.44%
KYTX Kyverna Therapeutics	0.00%	-15.90%	+21.76%	+22.27%	-60.89%
NMRA Neumora Therapeutics	0.00%	-13.12%	+6.89%	-30.97%	-91.48%
RAPT Rapt Therapeutics	0.00%	-14.91%	-3.72%	-29.20%	-70.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKTX Akari Therapeutics	0.5196 of 5 stars	0.0	3.0	0.0	2.0	1.7	0.0
KYTX Kyverna Therapeutics	2.6337 of 5 stars	3.6	3.0	0.0	2.0	1.7	0.6
NMRA Neumora Therapeutics	1.5193 of 5 stars	3.1	0.0	0.0	0.6	2.5	1.3
RAPT Rapt Therapeutics	3.8924 of 5 stars	3.2	1.0	4.2	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	0.00	N/A	N/A	N/A
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	502.61% Upside
NMRA Neumora Therapeutics	2.22	Hold	$9.29	1,081.84% Upside
RAPT Rapt Therapeutics	2.33	Hold	$24.00	223.01% Upside

Current Analyst Ratings Breakdown

Latest AKTX, NMRA, RAPT, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/13/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/10/2025	NMRA Neumora Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/3/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$6.00 ➝ $4.00
4/2/2025	NMRA Neumora Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Underperform	$7.00 ➝ $1.00
4/1/2025	KYTX Kyverna Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $20.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$0.84 per share	N/A
KYTX Kyverna Therapeutics	$7.03M	18.87	N/A	N/A	$6.17 per share	0.50
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
RAPT Rapt Therapeutics	$1.53M	80.32	N/A	N/A	$11.51 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$19.79M	N/A	0.00	∞	N/A	N/A	-213.59%	-65.60%	8/18/2025 (Estimated)
KYTX Kyverna Therapeutics	-$127.48M	-$3.38	N/A	N/A	N/A	N/A	-51.66%	-45.92%	8/11/2025 (Estimated)
NMRA Neumora Therapeutics	-$243.79M	-$1.61	N/A	N/A	N/A	N/A	-84.79%	-77.57%	8/5/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$2.40	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest AKTX, NMRA, RAPT, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	NMRA Neumora Therapeutics	-$0.40	-$0.42	-$0.02	-$0.42	N/A	N/A
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.16	0.16
KYTX Kyverna Therapeutics	N/A	7.44	7.44
NMRA Neumora Therapeutics	N/A	8.98	8.98
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
KYTX Kyverna Therapeutics	18.08%
NMRA Neumora Therapeutics	47.65%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	38.10%
KYTX Kyverna Therapeutics	22.00%
NMRA Neumora Therapeutics	26.80%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	32.18 million	19.92 million	Not Optionable
KYTX Kyverna Therapeutics	96	43.22 million	33.71 million	Optionable
NMRA Neumora Therapeutics	108	161.75 million	118.40 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

AKTX, NMRA, RAPT, and KYTX Headlines

Recent News About These Companies

Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?

June 18 at 1:41 PM | marketbeat.com

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

June 18 at 10:55 AM | zacks.com

RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics (NASDAQ:RAPT) Shares Scheduled to Reverse Split on Tuesday, June 17th

June 13, 2025 | marketbeat.com

RAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | finanznachrichten.de

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | globenewswire.com

Two Sigma Investments LP Sells 339,957 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

June 12, 2025 | marketbeat.com

Clear Street initiates Rapt Therapeutics stock with buy rating

June 7, 2025 | uk.investing.com

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

June 6, 2025 | msn.com

Rapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA hold

June 4, 2025 | fiercebiotech.com

RAPT Therapeutics to Participate in Upcoming Investor Conferences

June 4, 2025 | globenewswire.com

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Brokerages

June 3, 2025 | marketbeat.com

Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 39.9%

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for RAPT Q2 Earnings?

May 27, 2025 | marketbeat.com

12 Health Care Stocks Moving In Friday's Intraday Session

May 25, 2025 | benzinga.com

RAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street Zen

May 24, 2025 | marketbeat.com

UBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock Price

May 24, 2025 | marketbeat.com

RAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC Wainwright

May 24, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

May 16, 2025 | zacks.com

RAPT Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKTX, NMRA, RAPT, and KYTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$1.13 -0.02 (-1.83%)

Closing price 03:41 PM Eastern

Extended Trading

$1.13 +0.00 (+0.09%)

As of 04:37 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Kyverna Therapeutics NASDAQ:KYTX

$3.07 +0.16 (+5.50%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 +0.15 (+4.89%)

As of 06:28 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Neumora Therapeutics NASDAQ:NMRA

$0.79 +0.01 (+0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 +0.01 (+1.82%)

As of 06:58 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Rapt Therapeutics NASDAQ:RAPT

$7.43 +0.01 (+0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 +0.22 (+2.89%)

As of 04:20 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time